Immunological and functional characteristics of T memory-like cells in psoriasis under treatment with deucravacitinib - IM011-1115

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510759-37-00

Acronym

IM011-1115

Enrollment

Registered

2024-09-06

Start date

Unknown

Completion date

2025-05-05

Last updated

2025-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plaque Psoriasis

Brief summary

This is an explorative study which aims to analyze the impact of TYK-2i on TRM-like cells. To specifically evaluate the impact of TYK-2 inhibition with deucravacitinib on TRM-like CD4+-IL17A producing T cells, both quantitatively and in terms of functional activity, after 24 weeks of treatment.

Detailed description

To assess the correlation between the reduction in inflammatory infiltrating cells and cytokines (specifically IL-17/IL-22/IL-23) following TYK-2 inhibition with deucravacitinib and the potential impact on TRM-like cell dynamics. This

Interventions

DRUGSOTYKTU 6 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
This is an explorative study which aims to analyze the impact of TYK-2i on TRM-like cells. To specifically evaluate the impact of TYK-2 inhibition with deucravacitinib on TRM-like CD4+-IL17A producing T cells, both quantitatively and in terms of functional activity, after 24 weeks of treatment.	—

Secondary

Measure	Time frame
To assess the correlation between the reduction in inflammatory infiltrating cells and cytokines (specifically IL-17/IL-22/IL-23) following TYK-2 inhibition with deucravacitinib and the potential impact on TRM-like cell dynamics. This	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026